Featured Articles

  • Unpacking cell and gene therapy progress

    Friday, June 13, 2025
    Against a backdrop of historic charm, bold visions for the future of medicine were exchanged as attendees from all over the globe showed up in force to learn, present, collaborate and reconnect on all aspects of cell and gene therapies. read more

  • ISCT 2025 takeaways

    Friday, June 13, 2025
    ISCT is an important event for meeting leaders in the field of cell therapy, exploring the biggest challenges and bottlenecks, and mapping out potential solutions. read more

  • ASGCT takeaways

    Friday, June 13, 2025
    ASGCT is an important meeting to get a lay-of-the-land for the research and early-stage progress for the field of gene therapy, and to help identify the key trends going into the next decade of development for advanced therapies. read more

  • Navigating nuanced CGT clinical trial logistics

    Wednesday, June 11, 2025
    Advances in interactive response technology platforms for drug supply can be highly beneficial when thoughtfully designed to address the unique challenges of CGT trials. This is especially true when these platforms are integrated into a ... read more

  • Optimizing seed train processes

    Monday, June 02, 2025
    As the CGT space grows, making therapies available to more patients will require an all-encompassing approach to improving efficiency to lower manufacturing costs. New seed train technologies can not only improve viral vector manufacturing ... read more

  • Precision logistics for complex therapies

    Wednesday, May 28, 2025
    Patient-specific therapies come with unique logistics that bring added complexity and risk to supply chains. Manufacturing these therapies will continue to require robust supply chain management, stringent quality control and specialized ... read more

  • Overcoming CGT starting material challenges

    Wednesday, May 21, 2025
    Much of the focus for making CGTs accessible and commercially viable has looked downstream at manufacturing, logistics, geography, centralization, and even intellectual property. However, the vast majority of ex vivo advanced therapies ... read more

  • Shooting for immune

    Tuesday, May 13, 2025
    While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift cell therapies to new ... read more

  • Above the noise: CGT developers focus on access to better treatments amid immunology boom

    Monday, May 05, 2025
    The urgency of unmet need has not evaded the CGT sector, which has executed a ‘strategic pivot’ into autoimmune disease. Developers with B-cell targeting therapies originally designed to detect and kill cancer cells have recognized the ... read more

  • From bispecifics and ADCs to better reagents

    Wednesday, April 30, 2025
    Advances have allowed for the creation of bispecific, ‘Fc-silenced,’ and other specialized antibody reagents tailored to specific research needs. These engineered antibodies are deepening our understanding of complex biological systems and ... read more

  • Advancing AAV production

    Friday, March 28, 2025
    As the therapeutic potential of AAV gene therapy becomes increasingly evident, so does the demand for its widespread application; however, this surge in demand poses a formidable challenge in the need for increasingly scalable and efficient... read more

  • Orchestrating cell and gene therapies

    Tuesday, March 25, 2025
    An effective orchestration platform is now essential in optimizing processes, fostering collaboration, and ensuring the safe and effective administration of CGTs. These orchestration platforms are crucial tools for approved treatment center... read more
Page